A Study To Compare The Effectiveness Of Tofacitinib 11 Mg Once A Day To

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

It is hypothesized that patients prescribed tofacitinib 11 mg Modified Release (MR) formulation once daily (QD) will achieve similar benefit to those prescribed tofacitinib 5 mg twice a day (BID) dosage in real world use. This study will therefore seek to compare the effectiveness of the MR 11 mg QD regimen to the IR 5 mg BID regimen for the treatment of RA in a real-world registry of RA patients.

See also
Status	Clinical Trial	Phase
Completed	`NCT04267614` - This Study is to Investigate the Effect of Etanercept in Early Versus Delayed Referral for Management of Rheumatoid Arthritis Patients.
Completed	`NCT05932433` - Effectiveness of Therapeutic Exercise on the Gut Microbiome in Chronic Widespread Pain Patients.	N/A
Completed	`NCT04721821` - Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.

NCT number	NCT04267380
Study type	Observational
Source	Pfizer
Contact
Status	Completed
Phase
Start date	September 30, 2018
Completion date	August 31, 2019

A Study To Compare The Effectiveness Of Tofacitinib 11 Mg Once A Day To Tofacitinib 5 Mg Twice A Day

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms